Literature DB >> 6474527

Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Cerebral Embolism Study Group.

.   

Abstract

The clinical implications of hemorrhagic transformation of embolic brain infarction were explored by studying 30 patients with cardiogenic brain embolism and either hemorrhagic infarct (HI) or intracerebral hematoma (ICH) on CT. At the time of identification of hemorrhage, 19 patients were receiving anticoagulants and 11 were not. Eight anticoagulated patients and three nonanticoagulated patients developed late HI without attendant worsening after an initial CT was nonhemorrhagic. Hemorrhagic transformation without worsening most often occurred after 12 hours but before 48 hours following stroke onset and was associated with large infarcts (82%) but not with age, blood pressure or embolic source. Seven anticoagulated patients, six with large infarcts, and one nonanticoagulated patient with a small infarct abruptly worsened from eight hours to 11 days after stroke, with CT revealing ICH or severe HI. Excessive anticoagulation or acute hypertension potentially contributed to hemorrhagic transformation in four of five patients who were receiving heparin. Brain hemorrhage in embolic strokes most often occurs with large infarcts. Early CT may not allow the identification of large embolic infarcts that are destined to later undergo spontaneous hemorrhagic transformation. For large embolic infarcts, a delay of several days before anticoagulation and special efforts to avoid excessive anticoagulation and hypertension may be prudent. The initial administration of large, bolus doses of heparin should perhaps be avoided.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474527     DOI: 10.1161/01.str.15.5.779

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

1.  Why did we perform a lumbar puncture in a young patient with ischemic stroke?

Authors:  R Geraldes; A C Fonseca; P Canhão; T P Melo; J M Ferro
Journal:  J Neurol       Date:  2012-01-05       Impact factor: 4.849

Review 2.  Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.

Authors:  D J H McCabe; R D Rakhit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

3.  Symptomatic intracerebral hematomas in posterior circulation stroke patients anticoagulated with heparin.

Authors:  Kyusik Kang; Byung-Woo Yoon
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

4.  Intracranial hemorrhage in infective endocarditis: A case report.

Authors:  Fahad Aziz; Saira Perwaiz; Sudheer Penupolu; Sujatha Doddi; Srinivas Gongireddy
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

Review 5.  Drug treatment of stroke. Current status and future prospects.

Authors:  C A Sila; A J Furlan
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

6.  Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage.

Authors:  T F Choudhri; B L Hoh; C J Prestigiacomo; J Huang; L J Kim; A M Schmidt; W Kisiel; E S Connolly; D J Pinsky
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

7.  Hemorrhagic cardioembolic stroke secondary to a left ventricular thrombus: a therapeutic dilemma.

Authors:  Khalil Al-Farsi; Aftab A Siddiqui; Yasser W Sharef; Ali K Al-Belushi; Hakeem Al-Hashim; Mohammed Al-Ghailani; William J Johnston
Journal:  Oman Med J       Date:  2013-01

Review 8.  Plasminogen activators and ischemic stroke: conditions for acute delivery.

Authors:  Gregory J del Zoppo
Journal:  Semin Thromb Hemost       Date:  2013-03-28       Impact factor: 4.180

9.  Complex atheromatosis of the aortic arch in cerebral infarction.

Authors:  Ramón Pujadas Capmany; Montserrat Oliveras Ibañez; Xavier Jané Pesquer
Journal:  Curr Cardiol Rev       Date:  2010-08

10.  Heparin 1986. Indications and effective use.

Authors:  P Ockelford
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.